Title

Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

Authors

Carolin Heller BSc1, Martha S. Foiani MRes1, Katrina M. Moore BSc2, Rhian S. Convery MSc2, Martina Bocchetta PhD2, Mollie Neason MSc2, David M. Cash PhD2, David L. Thomas PhD3, Caroline V. Greaves BSc2, Ione O.C. Woollacott MRCP2, Rachelle Shafei MRCP2, John van Swieten MD4, Fermin Moreno MD5, Raquel Sanchez-Valle MD6, Barbara Borroni MD7, Robert Leforce Jr MD PhD8, Mario Masellis MD PhD9, Maria Carmela Tartaglia MD10, Caroline Graff MD11, Daniela Galimberti PhD12, James B. Rowe FRCP PhD14, Elizabeth Finger MD15, Matthias Synofzik MD16,17, Rik Vandenberghe MD18, Alexandre de Mendonça MD19, Fabrizio Tagliavini MD20, Isabel Santana MD21, Simon Ducharme MD22, Chris Butler FRCP PhD23, Alex Gerhard FRCP PhD24, Johannes Levin MD25,26,27, Adrian Danek MD25, Giovanni Frisoni PhD26, Sandro Sorbi PhD26, Markus Otto MD30, Amanda Heslegrave PhD1, Henrik Zetterberg PhD1,31, Jonathan D. Rohrer FRCP PhD2 on behalf of GENFI*

*List of consortium authors below

Affiliations

1UK Dementia Research Institute, 2Dementia Research Centre, Department of Neurodegenerative Disease, and 3Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology, London, UK. 4Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands. 5Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain. 6Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain. 7Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. 8Clinique Interdisciplinaire de Mémoire du CHU de Québec, Département des Sciences Neurologiques, Université Laval, Québec, Canada. 9Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada. 10Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada. 11Department of Geriatric Medicine, Karolinska University Hospital-Huddinge, Stockholm, Sweden. 12Dept. of Biomedical, Surgical and Dental Sciences, University of Milan, Centro Dino
Ferrari, Milan, Italy. 13Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. 14Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom. 15Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario Canada. 16Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany. 17German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany. 18Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium. 19Faculty of Medicine, University of Lisbon, Lisbon, Portugal. 20Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Neurologica Carlo Besta, Milano, Italy. 21Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 22Department of Neurology and Neurosurgery, McGill University, Montreal, Québec, Canada. 23Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom. 24Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK. 25Department of Neurology, Ludwig-Maximilians-University, Munich, Germany. 26German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. 27Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. 28Instituto di Recupero e Cura a Carattere Scientifco Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy. 29Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy. 30Department of Neurology, University of Ulm, Ulm. 31Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.

**Corresponding author**

Dr Jonathan Rohrer, Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, WC1N 3BG, +4420 344 83039, j.rohrer@ucl.ac.uk

Number of words: abstract 285; main text 3750
List of GENFI consortium authors:

Martin N. Rosser MD FRCP, Jason D. Warren PhD FRACP, Nick C. Fox MD FRCP, Jose Bras PhD, Jennifer Nicholas PhD, Simon Mead PhD, Lize Jiskoot PhD, Lieke Meeter MD, Jessica Panman MSC, Janne Papma PhD, Rick van Minkelen PhD, Yolanda Pijnenburg PhD, Myriam Barandiaran PhD, Begoña Indakoeetxea MD, Alazne Gabilondo MD, Mikael Tainta MD, Maria de Arriba BSc, Ana Gorostidi PhD, Miren Zulaica BSc, Jorge Villanua MD PhD, Ziggor Diaz, Sergi Borrego-Ecija MD, Jaume Olives MSC, Albert Lladó PhD, Mircea Balasa PhD, Anna Antonell PhD, Nuria Bargallo PhD, Enrico Premi MD, Maura Cosseddu MPsych, Stefano Gazzina MD, Alessandro Padovani MD PhD, Roberto Gasparotti MD, Silvana Archetti MBiolSci, Sandra Black MD, Sara Mitchell MD, Ekaterina Rogaeva PhD, Morris Freedman MD, Ron Keren MD, David Tang-Wai MD, Linn Öijerstedt MD, Chrisitn Andersson PhD, Vesna Jelic MD, Hakan Thonberg MD, Andrea Arighi MD, Chiara Fenoglio PhD, Elio Scarpini MD, Giorgio Fumagalli MD, Thomas Cope MRC, Carolyn Timberlake BSc, Timothy Rittman MRC, Christen Shoesmith MD, Robert Bartha PhD, Rosa Rademakers PhD, Carlo Wilke MD, Hans-Otto Karnarth MD, Benjamin Bender MD, Rose Bruuffaerts MD PhD, Philip Vandamme MD PhD, Mathieu Vandenbulcke MD PhD, Catarina B. Ferreira MSC, Gabriel Miltenberger PhD, Carolina Maruta MPsych PhD, Ana Verdelho MD PhD, Sónia Afonso BSc, Ricardo Taipa MD PhD, Paola Caroppo MD PhD, Giuseppe Di Fede MD PhD, Giorgio Giaccone MD, Sara Prioni PsyD, Veronica Redaelli MD, Giacomina Rossi MSC, Pietro Tiraboschi MD, Diana Duro NPsych, Maria Rosario Almeida PhD, Miguel Castelo-Branco MD PhD, Maria João Leitão BSc, Miguel Tabus-Pereira MD, Beatriz Santiago MD, Serge Gauthier MD, Pedro Rosa-Neto MD PhD, Michele Veldsman PhD, Toby Flanagan BSc, Catharina Prie MD, Tobias Hoegen MD, Elisabeth Wlasich Mag. rer. nat., Sandra Loosli MD, Sonja Schonecker MD, Elisa Semler Dr.hum.biol Dipl. Psych, Sarah Anderl-Straub Dr.hum.biol Dipl.Psych, Luisa Benussi PhD, Giuliano Binetti PhD, Roberta Ghidoni PhD, Michela Pievani PhD, Gemma Lombardi MD, Benedetta Nacmias PhD, Camilla Ferrari, Valentina Bessi.

Affiliations:

1Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; 2Dementia Research Institute, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; 3Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, Michigan, USA; 4Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK; 5MRC Prion Unit, Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK; 6Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands; 7Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, Netherlands; 8Amsterdam University Medical Centre, Amsterdam VUmc, Amsterdam, Netherlands; 9Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain; 10Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain; 11OSATEK, University of Donostia, San Sebastian, Gipuzkoa, Spain; 12CITA Alzheimer, San Sebastian, Gipuzkoa, Spain; 13Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain; 14Imaging Diagnostic Center, Hospital Clinic, Barcelona, Spain; 15Centre for Neurodegenerative Disorders, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 16Neuroradiology Unit, University of Brescia, Brescia, Italy; 17Biotechnology Laboratory, Department of Diagnostics, Spedali Civili Hospital, Brescia, Italy; 18Clinique Interdisciplinaire de Mémoire Département des Sciences Neurologiques Université Laval Québec, Quebec, Canada; 19Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada; 20Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada; 21Baycrest Health Sciences, Rotman Research Institute, University of Toronto, Toronto, Canada; 22The University Health Network, Toronto Rehabilitation Institute, Toronto, Canada; 23The University Health Network, Krembil Research Institute, Toronto, Canada; 24Department of Geriatric Medicine, Karolinska...
ABSTRACT

Background: There are few validated fluid biomarkers in FTD. Glial fibrillary acidic protein (GFAP) is a measure of astrogliosis, a known pathological process of FTD, but has yet to be explored as potential biomarker.

Methods: Plasma GFAP and neurofilament light chain (NfL) concentration were measured in 469 individuals enrolled in the Genetic FTD Initiative (GENFI): 114 C9orf72 expansion carriers (74 presymptomatic, 40 symptomatic), 119 GRN mutation carriers (88 presymptomatic, 31 symptomatic), 53 MAPT mutation carriers (34 presymptomatic, 19 symptomatic) and 183 non-carrier controls. Biomarker measures were compared between groups using linear regression models adjusted for age and sex with family membership included as random effect. Participants underwent standardized clinical assessments including the Mini-Mental State Examination (MMSE), Frontotemporal Lobar Degeneration-Clinical Dementia Rating scale (FTLD-CDR), and magnetic resonance imaging (MRI). Spearman’s correlation coefficient was used to investigate the relationship of plasma GFAP to clinical and imaging measures.

Results: Plasma GFAP concentration was significantly increased in symptomatic GRN mutation carriers (adjusted mean difference from controls 192.3 pg/mL, 95% confidence intervals 126.5-445.6), but not in those with C9orf72 expansions (9.0, -61.3-54.6), MAPT mutations (12.7, -33.3-90.4) or the presymptomatic groups. GFAP concentration was significantly positively correlated with age in both controls and the majority of the disease groups, as well as with NfL concentration. In the presymptomatic period, higher GFAP concentrations were correlated with a lower cognitive score (MMSE) and lower brain volume, whilst in the symptomatic period, higher concentrations were associated with faster rates of atrophy in the temporal lobe.

Conclusions: Raised GFAP concentrations appear to be unique to GRN-related FTD, with levels potentially increasing just prior to symptom onset, suggesting that GFAP may be an important marker of proximity to onset, and helpful for forthcoming therapeutic prevention trials.
INTRODUCTION

Frontotemporal dementia (FTD) is a progressive neurodegenerative condition with around a third of cases caused by an autosomal dominant gene mutation in progranulin (GRN), chromosome 9 open reading frame 72 (C9orf72) or microtubule-associated protein tau (MAPT). As clinical trials in genetic FTD are fast approaching, robust biomarkers that allow accurate measurement of disease onset and progression are becoming increasingly important. In particular, many trials will focus on the presymptomatic stage of disease where neuropathological alterations are already present and yet few biomarkers have been shown to be abnormal in this phase.

Cerebrospinal fluid (CSF) or plasma/serum progranulin levels in GRN mutation carriers and CSF (poly)GP dipeptide repeat concentrations in C9orf72 expansion carriers are markers of specific protein abnormalities in genetic FTD but both are abnormal from early in the presymptomatic period (and potentially from birth). In contrast, neurofilament light chain (NfL) is a marker of neuronal death and axonal degeneration (measurable in CSF as well as both plasma and serum) that is not specific to FTD and has only been shown to be abnormal in the very late presymptomatic period prior to conversion to the symptomatic phase. Glial fibrillary acidic protein (GFAP) is a marker of astrogliosis, the abnormal proliferation of astrocytes due to neuronal damage, and has previously been shown to be increased in frontal cortical tissue in FTD, and raised in both the CSF and serum of patients with symptomatic FTD. However, it has yet to be explored using ultrasensitive blood-based assays in genetic FTD mutation carriers.

In this study, we aimed to investigate within the Genetic FTD Initiative (GENFI) cohort whether plasma GFAP was abnormal in each of the different genetic FTD groups during the symptomatic period, and whether we could detect any presymptomatic changes. We also aimed to explore the relationship of GFAP with plasma NfL and with cognitive and neuroimaging measures.
METHODS

Participants
Participants were recruited from GENFI, a natural history study of genetic FTD involving 23 research centres across Europe and Canada (www.genfi.org.uk) involving symptomatic carriers of mutations in GRN, MAPT, or C9orf72, and those at risk of carrying a mutation because a first-degree relative was a known symptomatic carrier. 469 consecutively recruited individuals from the GENFI study were included: 114 C9orf72 expansion carriers (74 presymptomatic, 40 symptomatic), 119 GRN mutation carriers (88 presymptomatic, 31 symptomatic), 53 MAPT mutation carriers (34 presymptomatic, 19 symptomatic) and 183 non-carriers who acted as a control group. Demographic information is shown in Table 1: age and sex differed significantly between groups. All people in the study underwent a clinical assessment consisting of a medical history with the participant and informant, and physical examination, with symptomatic status diagnosed by a clinician who was an expert in the FTD field specific diagnoses are shown in Table 1. All participants underwent a standardized examination including the Mini-Mental State Examination (MMSE) and the Frontotemporal Lobar Degeneration Clinical Dementia Rating scale (FTLD-CDR). Participants also performed 3D T1-weighted magnetic resonance imaging (MRI) of the brain: 432 scans were available for cross-sectional analysis, of which a subgroup of 243 participants had a follow-up scan (on the same scanner) for analysis [mean (standard deviation) interval 1.12 (0.29) years between baseline and follow-up]. Volumetric measures of whole brain and cortical regions were calculated using a previously described method that uses the geodesic information flow (GIF) algorithm, which is based on atlas propagation and label fusion (Supplementary Table 1). An annualized longitudinal rate of atrophy was found by calculating the difference in each specific measure between the baseline and longitudinal scan and expressing it as a percentage of the baseline volume over one year (Supplementary Table 2). Local ethics committees at each site approved the study and all participants provided written informed consent at enrolment.
Table 1: Demographic, cognitive and biomarker data from study participants. IQR – Interquartile range; MMSE – Mini-Mental State Examination; FTLD-CDR-SOB – Frontotemporal Lobar Degeneration Clinical Dementia Rating scale Sum Of Boxes; GFAP – Glial fibrillary acidic protein; NfL – Neurofilament light chain protein. For sex, age, MMSE and FTLD-CDR-SOB, significant differences (p < 0.05) are shown in the table as follows: a. compared to controls, b. in C9orf72 group between symptomatic and presymptomatic carriers, c. in GRN group between symptomatic and presymptomatic carriers, d. in MAPT group between symptomatic and presymptomatic carriers.

<table>
<thead>
<tr>
<th></th>
<th>Controls</th>
<th>Presymptomatic mutation carriers</th>
<th>Symptomatic mutation carriers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>C9orf72</td>
<td>GRN</td>
</tr>
<tr>
<td>Number of participants</td>
<td>183</td>
<td>74</td>
<td>88</td>
</tr>
<tr>
<td>Sex: number male (%)</td>
<td>81 (44.3)</td>
<td>29 (39.2)</td>
<td>34 (38.6)</td>
</tr>
<tr>
<td>Median (IQR) age (years)</td>
<td>43.8 (36.3 - 55.1)</td>
<td>44.1 (34.4 - 52.9)</td>
<td>42.4 (34.6 - 52.7)</td>
</tr>
<tr>
<td>Mean (range) age at onset (years)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Median (IQR) disease duration (years)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Median (range) MMSE (years)</td>
<td>30 (26 - 30)</td>
<td>30 (25 - 30)</td>
<td>30 (26 - 30)</td>
</tr>
<tr>
<td>Median (range) FTLD-CDR-SOB</td>
<td>0.0 (0.0 - 3.0)</td>
<td>0.0 (0.0 - 3.0)</td>
<td>0.0 (0.0 - 2.5)</td>
</tr>
<tr>
<td>Median (IQR) plasma NfL (pg/mL)</td>
<td>9.3 (6.8 - 13.0)</td>
<td>11.3 (8.3 - 17.0)</td>
<td>9.2 (7.0 - 12.8)</td>
</tr>
<tr>
<td>Median (IQR) plasma GFAP (pg/mL)</td>
<td>105.8 (80.4 - 146.1)</td>
<td>116.1 (88.3 - 180.0)</td>
<td>113.4 (80.5 - 168.1)</td>
</tr>
</tbody>
</table>
Measurement of plasma markers

Plasma was collected, processed and stored in aliquots at -80°C according to standardised procedures. Samples were measured using the multiplex Neurology 4-Plex A kit (102153, Quanterix Corporation, Lexington, USA) on the SIMOA HD-1 Analyzer following manufacturer’s instructions. The lower limit of detection of the assay for GFAP and NfL were 0.221 pg/mL and 0.104 pg/mL respectively. Measurements were carried out at the same study site on consecutive days and the operator was blinded to all clinical information, including genetic status. To keep sample processing and plating consistent, plasma samples were thawed at room temperature for two hours and subsequently centrifuged at 10,000g for five minutes. 150µL samples were aliquoted in a 96-well plate (Quanterix Corporation, Lexington, USA) and frozen at -80°C until analysis. Quality control (QC) samples had a mean intra-assay and inter-assay coefficient of variation (CV) of less than 10%.

Statistical analysis

Fisher’s exact test was used to compare sex frequencies between groups. Distributions for demographic and biomarker data were investigated graphically using histograms and quantile-quantile plots and tested for normality using the Shapiro-Wilk test. As demographic data did not follow a normal distribution, group differences for age at sample collection and FTLD-CDR-SOB were compared using the Kruskal-Wallis test. A linear regression adjusting for age was used to compare MMSE scores between groups. The primary analysis in the study was to investigate whether there were any differences in plasma GFAP concentration from controls in the different genetic mutation groups both symptomatically and presymptomatically, as well as between genetic groups. As biomarker values were not normally distributed, group means were compared by performing a linear mixed regression model with 95% bias-corrected bootstrapped confidence intervals with 2000 repetitions in STATA (v.14; Texas, USA), adjusting for age and sex with family membership included as a random effect. Diagnostic performance of GFAP was assessed by areas under the curve (AUC) obtained by receiver operating characteristic (ROC) analyses, with optimal cut-off levels at the highest
Youden’s index (sensitivity + specificity - 1) using GraphPad Prism V.6 (GraphPad Software, San Diego, California, USA). In order to investigate the relationship of GFAP concentration to demographic, cognitive and imaging measures as well as NfL concentrations, Spearman’s correlation coefficient was used.

RESULTS

Plasma GFAP concentration
Plasma GFAP concentration was significantly higher in the symptomatic GRN mutation carriers compared to controls (adjusted mean difference 192.3 pg/mL, 95% confidence intervals 126.5-445.6), but not in either the symptomatic C9orf72 (9.0, -61.3-54.6) or MAPT (12.7, -33.3-90.4) groups (Figure 1, Tables 1 and 2). Within the symptomatic groups, concentrations in GRN were significantly higher than both C9orf72 (183.3, 106.1-427.2) and MAPT (179.6, 99.8-348.1) mutation carriers.

A receiver operating characteristic curve analysis measuring the ability of GFAP to distinguish symptomatic GRN mutation carriers from controls showed a sensitivity of 90.3% and specificity of 82.0% with a cut-off point of 163.2 pg/mL and an area under the curve (AUC) of 0.90. For distinguishing symptomatic GRN mutation carriers from C9orf72 mutation carriers there was a sensitivity of 71.0% and specificity of 70.0% with a cut-off point of 226.2 pg/mL and an AUC of 0.74, whilst for distinguishing symptomatic GRN mutation carriers from MAPT mutation carriers there was a sensitivity of 79.0% and specificity of 77.4% with a cut-off point of 209.1 pg/mL and an AUC of 0.80 (Supplementary Figure 1).

In the presymptomatic groups, concentrations were not significantly increased in any of the groups compared to controls: GRN (14.2, -2.4-38.3), C9orf72 (21.1, -18.8-66.5), MAPT (-7.0, -61.8-7.8) (Figure 1, Tables 1 and 2). There were also no differences across the presymptomatic groups.
Comparing symptomatic and presymptomatic carriers, a significantly higher concentration was also seen in the symptomatic versus the presymptomatic GRN mutation carriers (178.1, 114.3-365.2), but not in the other groups (Figure 1, Tables 1 and 2).

Table 2. Adjusted mean differences in plasma GFAP concentrations between groups with 95% bias-corrected bootstrap confidence intervals. Significant differences in bold: ** p < 0.01. PS – presymptomatic; S – symptomatic.

<table>
<thead>
<tr>
<th>GFAP</th>
<th>C9orf72 PS</th>
<th>C9orf72 S</th>
<th>GRN PS</th>
<th>GRN S</th>
<th>MAPT PS</th>
<th>MAPT S</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>21.1</td>
<td>9.0</td>
<td>14.2</td>
<td>192.3**</td>
<td>-7.0</td>
<td>12.7</td>
</tr>
<tr>
<td></td>
<td>(-18.8, 66.5)</td>
<td>(-61.3, 54.6)</td>
<td>(-2.4, 38.3)</td>
<td>(126.5, 445.6)</td>
<td>(-61.8, 7.8)</td>
<td>(-33.3, 90.4)</td>
</tr>
<tr>
<td>C9orf72 PS</td>
<td>12.1</td>
<td>-6.9</td>
<td>171.2**</td>
<td>-28.1</td>
<td>8.4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(-64.1, 85.1)</td>
<td>(-51.0, 43.0)</td>
<td>(88.5, 433.7)</td>
<td>(-83.3, 8.0)</td>
<td>(-87.5, 74.5)</td>
<td></td>
</tr>
<tr>
<td>C9orf72 S</td>
<td>-5.2</td>
<td>183.3**</td>
<td>-16.0</td>
<td>-3.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(-79.4, 39.4)</td>
<td>(106.1, 427.2)</td>
<td>(-84.3, 32.9)</td>
<td>(-104.5, 56.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRN PS</td>
<td>178.1**</td>
<td>-21.2</td>
<td>1.5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(114.3, 365.2)</td>
<td>(-78.3, 1.5)</td>
<td>(-75.4, 49.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRN S</td>
<td>-199.3**</td>
<td>-179.6**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(-439.2, -124.9)</td>
<td>(-348.1, -99.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAPT PS</td>
<td>19.6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(-30.8, 114.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Correlation with age

GFAP concentration was significantly correlated with age at sample collection in controls (r=0.55, p<0.001), presymptomatic mutation carriers (all groups combined: r=0.53, p<0.001; GRN: r=0.58, p<0.001; C9orf72: r=0.50, p<0.001; MAPT: r=0.36, p= 0.036), and symptomatic mutation carriers for all genetic groups together (r=0.38, p<0.001) and the GRN group alone (r=0.65, p<0.001) (Figure 2). No significant correlation was seen for the symptomatic C9orf72 (r=0.27, p=0.088) or MAPT mutation carriers (r=0.00, p=0.989).
**Correlation with plasma NfL**

Plasma NfL was increased in all three symptomatic groups compared with controls (Figure 1, Tables 1 and 3): GRN mutation carriers (adjusted mean difference 70.5 pg/mL, 95% confidence intervals 51.6-92.6), C9orf72 mutation carriers (29.7, 18.7-47.5), and MAPT mutation carriers (12.6, 3.3-26.1). Within the symptomatic groups, concentrations in GRN were significantly higher than both C9orf72 (40.7, 16.5-62.2) and MAPT (57.9, 36.8-81.5) mutation carriers, and C9orf72 mutation carriers were higher than MAPT mutation carriers (17.2, 2.9-35.7). Concentration was also increased in presymptomatic C9orf72 mutation carriers compared with controls (9.0, 1.3-26.8), but not in the GRN or MAPT presymptomatic groups (Figure 1, Tables 1 and 3). Comparing symptomatic and presymptomatic carriers, a significantly higher concentration was also seen in the symptomatic versus the presymptomatic mutation carriers in each of the groups (Figure 1, Tables 1 and 3): GRN mutation carriers (70.5, 52.5-92.2), C9orf72 mutation carriers (20.7, 3.2-36.1), and MAPT mutation carriers (11.7, 0.8-23.4).

Plasma GFAP and NfL concentrations were significantly correlated in controls ($r=0.66$, $p<0.001$), presymptomatic mutation carriers (GRN: $r=0.66$, $p<0.001$; C9orf72: $r=0.75$, $p<0.001$; MAPT: $r=0.41$, $p=0.017$), and symptomatic mutation carriers (GRN: $r=0.38$, $p=0.036$; C9orf72: $r=0.57$, $p<0.001$; MAPT: $r=0.76$, $p<0.001$).

**Table 3. Adjusted mean differences in plasma NfL concentrations between groups with 95% bias-corrected bootstrap confidence intervals. Significant differences in bold: * $p < 0.05$; ** $p < 0.01$. PS – presymptomatic; S – symptomatic.**

<table>
<thead>
<tr>
<th>NfL</th>
<th>C9orf72 PS</th>
<th>C9orf72 S</th>
<th>GRN PS</th>
<th>GRN S</th>
<th>MAPT PS</th>
<th>MAPT S</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>9.0*</td>
<td>29.7**</td>
<td>0.0</td>
<td>70.5**</td>
<td>0.9</td>
<td>12.6*</td>
</tr>
<tr>
<td></td>
<td>(1.3, 26.8)</td>
<td>(18.7, 47.5)</td>
<td>(-3.1, 3.3)</td>
<td>(51.6, 92.6)</td>
<td>(-2.2, 6.4)</td>
<td>(3.3, 26.1)</td>
</tr>
<tr>
<td></td>
<td>20.7*</td>
<td>-9.0*</td>
<td>61.4**</td>
<td>-8.1*</td>
<td>3.6</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(3.2, 36.1)</td>
<td>(-27.5, -1.4)</td>
<td>(37.7, 82.7)</td>
<td>(-27.0, -0.6)</td>
<td>(-15.6, 17.0)</td>
<td></td>
</tr>
<tr>
<td>C9orf72 PS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C9orf72 S</td>
<td>-29.8**</td>
<td>40.7**</td>
<td>-28.9**</td>
<td>-17.2*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(-47.7, -18.7)</td>
<td>(16.5, 62.2)</td>
<td>(-46.2, -16.9)</td>
<td>(-35.7, -2.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRN PS</td>
<td></td>
<td>70.5**</td>
<td>-0.9</td>
<td>12.6*</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(52.5, 92.2)</td>
<td>(-5.9, 2.9)</td>
<td>(2.9, 25.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRN S</td>
<td></td>
<td></td>
<td>-69.6**</td>
<td>-57.9**</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(-91.7, -50.6)</td>
<td>(-81.5, -36.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAPT PS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11.7*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(0.8, 23.4)</td>
<td></td>
</tr>
</tbody>
</table>

**Correlation with cognitive measures**

A significant negative correlation between GFAP concentrations and MMSE was seen in the presymptomatic GRN ($r=-0.24$, $p=0.033$) and C9orf72 ($r=-0.40$, $p<0.001$) but not MAPT ($r=0.05$, $p=0.801$) mutation carriers. No significant correlation was seen during the symptomatic period in any of the genetic groups (GRN: $r=-0.29$, $p=0.153$; C9orf72: $r=-0.24$, $p=0.146$; MAPT: $r=-0.48$, $p=0.080$).

No significant correlations were seen between GFAP concentration and FTLD-CDR sum of boxes score in either the presymptomatic or symptomatic period in any group: GRN: $r=-0.04$, $p=0.768$ presymptomatic, $r=0.18$, $p=0.409$ symptomatic; C9orf72: $r=-0.17$, $p=0.234$ presymptomatic, $r=0.21$, $p=0.321$ symptomatic; MAPT: $r=-0.17$, $p=0.446$ presymptomatic, $r=0.14$, $p=0.736$ symptomatic.

**Correlation with cross-sectional imaging data**

A significant negative correlation was seen between GFAP concentrations and both GRN and C9orf72 presymptomatic carrier brain volumes for frontal cortex ($r=-0.23$, $p=0.039$; $r=-0.35$, $p=0.002$), temporal cortex ($r=-0.35$, $p=0.001$; $r=-0.27$, $p=0.024$), cingulate cortex ($r=-0.24$, $p=0.027$; $r=-0.44$, $p<0.001$), and insular cortex ($r=-0.27$, $p=0.016$; $r=-0.26$, $p=0.029$) as well as whole brain ($r=-0.45$, $p<0.001$) and parietal cortex ($r=-0.33$, $p=0.005$) for the C9orf72 group (Supplementary Table 3). No significant correlations
were seen in the presymptomatic MAPT mutation carrier group or any of the symptomatic genetic groups.

**Correlation with longitudinal imaging data**

No significant positive correlation of GFAP concentration with longitudinal rates of atrophy were seen in any of the groups except for in the temporal cortex of symptomatic GRN mutation carriers ($r=0.66$, $p=0.010$) (Supplementary Table 4). However, within the same symptomatic GRN group there was also a trend in relationship between GFAP concentration and atrophy rates in the cingulate cortex ($r=0.55$, $p=0.052$).

**DISCUSSION**

In this study, we found that plasma GFAP concentration was significantly increased in genetic FTD but only in GRN mutation carriers, and not in those with C9orf72 expansions or mutations in the MAPT gene. In the presymptomatic period, higher concentrations were correlated with a lower cognitive score (MMSE) and lower brain volumes (in regions characteristically affected in FTD), potentially suggesting GFAP is increased in the late presymptomatic period. In the symptomatic period, higher concentrations were associated with faster rates of atrophy, suggesting GFAP levels are associated with disease intensity, and therefore progression and survival.

GFAP is a major constituent of the astrocytic cytoskeleton and its expression pattern is highly brain-enriched. Its levels increase following acute damage to astrocytes such as after a stroke or traumatic brain injury, but also in relation to more chronic insults, such as in neurodegeneration, when astrocytes become reactive, increasing in size and proliferating, a process called astrogliosis. In neurodegeneration, increased GFAP concentrations in biofluid have been reported in Alzheimer’s disease (in both CSF and serum) and amyotrophic lateral sclerosis. Previous studies in FTD have found increased CSF concentrations in symptomatic patients within combined clinical and...
genetic cohorts but have not previously found changes in blood, nor investigated individual genetic groups previously. Our results suggest that there are differential increases within FTD, with concentrations being higher in people with GRN mutations than in other groups. GRN encodes the progranulin protein, which is a secreted growth factor and known to be involved in many biological processes including inflammation, wound healing and cell proliferation. However, progranulin is also taken up by astrocytes for storage or transportation to the lysosomal compartment, and studies of GRN-deficient mice have shown the presence of astrogliosis. In vitro, progranulin seems to have a role of inactivating astrocytes with evidence that progranulin attenuates a pro-inflammatory phenotype of astrocytes. This suggests that deficiency of progranulin in GRN mutation carriers, may lead to activation of pro-inflammatory phenotypes of astrocytes and subsequent astrogliosis, with increased levels of GFAP protein expression. People with GRN mutations have evidence of astrogliosis pathologically, including within areas of white matter damage (visible in a proportion of people in vivo as white matter hyperintensities on MR imaging, which have been previously shown to be unique to GRN mutations within familial FTD). Such damage increases as the neurodegeneration progresses, consistent with the pattern of increased plasma GFAP in our study. In contrast, levels were not increased in plasma in individuals with C9orf72 expansions or MAPT mutations. Whilst astrogliosis is seen in animal models and at postmortem in both C9orf72- and MAPT-related FTD, this may well be a late feature of the disease, or the extent of astrogliosis may be less. Future work will be required to investigate this further.

It is well established that multiple biomarkers of neurodegeneration increase in concentration with age, attributed to the reduction of neural integrity in the ageing brain. CSF GFAP concentrations have previously been shown to increase as one gets older, with multiple studies showing proliferation of astrocytes, increased GFAP immunoreactivity, and elevated levels of GFAP mRNA with age. Consistent with this, we also found a significant positive correlation of plasma GFAP concentration with age in the majority of the groups. This highlights the importance of adjusting
plasma GFAP concentrations for age in statistical analyses: symptomatic mutation carriers in the C9orf72 and MAPT groups (as well as the GRN group) in this study showed increased levels of plasma GFAP compared to controls and their presymptomatic counterparts, but significance was lost once adjusting for age.

NfL, part of the axonal cytoskeleton, is released following cellular damage. A previous study has shown that NfL concentrations are increased in both the CSF and blood of symptomatic genetic FTD in all three mutation groups, C9orf72, GRN and MAPT. The results in this study replicate these findings in plasma, although we also found elevated levels in presymptomatic C9orf72 mutation carriers. In this latter group, NfL concentrations correlated negatively with MMSE (r=-0.33, p=0.004: Supplementary Table 5) and with brain volumes (whole brain, r=-0.53, p<0.001 and cortical regions: frontal, -0.51, <0.001; temporal, -0.37, 0.001; parietal, -0.51, <0.001; occipital, -0.33, 0.005; cingulate, -0.49, <0.001; insula, -0.47, <0.001: Supplementary Tables 6 and 7), suggesting that NfL increases particularly towards the end of the presymptomatic period with increasing neurodegeneration. Although GRN NfL concentration was not significantly increased presymptomatically, a similar pattern of negative correlation with brain volumes was seen in this group (in whole brain and all cortical regions except the occipital lobe, r=-0.30 to -0.48, p≤0.006). NfL and GFAP concentrations were significantly correlated in all groups including controls, although the correlation coefficient varied from 0.38 to 0.76. A similar correlation has been shown in CSF previously. As both increase with age (Supplementary Table 8 for NfL correlations with age), the correlation is not unexpected, but other unexplained factors are likely to affect the different patterns within genetic FTD; interestingly, the lowest correlation (r=0.38) was in the symptomatic GRN mutation carriers, suggesting that in this group astrogliosis and neurodegeneration are not so closely related.

Correlation of GFAP concentration with cognitive and imaging measures revealed a negative correlation i.e. higher concentration with a lower cognitive score and lower cross-sectional brain
volumes in FTD-related regions in presymptomatic GRN mutation carriers. This suggests that GFAP levels start to increase as the brain starts to decrease in volume, and as cognition starts to become affected thus in the later stages of the presymptomatic period in proximity to symptom onset. This would be an important biomarker for GRN-related FTD, as an increase in concentration from baseline during the presymptomatic period would identify a time around the onset of neurodegeneration, and potentially a time when therapeutic intervention may be optimal. Despite the lack of a significant increase in concentration in C9orf72 mutation carriers, a similar pattern of negative correlation with cognition and brain imaging was seen in the presymptomatic period – it would be useful in future studies to investigate the subset of C9orf72 expansion carriers that have increased GFAP concentrations, and how they differ from those with a lower concentration. In particular, it would be helpful to compare carriers with and without concomitant ALS. We also assessed whether GFAP correlated with the rate of brain atrophy measured with longitudinal brain imaging and found a significant positive correlation only in the symptomatic GRN carriers (in the temporal lobe), implicating an association of GFAP levels with the intensity of the disease process i.e. how fast the disease is progressing. With longitudinal follow-up of participants, it would therefore be hypothesized that higher GFAP concentration would be associated with shorter survival in GRN-related FTD.

Whilst the multicentre nature of the GENFI study allows collection of samples from a large genetic cohort of FTD worldwide, there remains a relatively small number of cases in each group (leading to low statistical power to detect differences), particularly in the symptomatic carriers, and replication in a larger dataset would be helpful. Due to the nature of the disease process, the mean age of the controls overall is lower compared to the symptomatic mutation carriers, but nonetheless the same results are found whether performing an age-adjusted comparison (as presented above) or when symptomatic mutation carriers are compared with an age- and gender-matched subset of older controls (see Supplementary Figure 2). The advantage of studying levels in plasma is that blood is
more easily accessible and a relatively cost-efficient way to access bodily fluids in comparison to performing a lumbar puncture; in this study, the use of the ultrasensitive Simoa assay allowed detection at a level in blood that other assays do not. However, it will be important to study CSF levels in more detail in this group, as concentrations can differ between blood and CSF\textsuperscript{18}. Lastly, despite significant differences between the groups, there is a substantial overlap in concentrations between carriers and controls: longitudinal study of GFAP concentration over time, particularly in participants that convert from presymptomatic to symptomatic status, will therefore be important to truly evaluate whether changes do occur towards the end of the presymptomatic period and how levels change with progression of disease.

In summary, plasma GFAP levels appear to be uniquely increased in \textit{GRN} mutation carriers in the current study, and importantly, concentrations may well be abnormal during the late presymptomatic period, suggesting that GFAP might act as marker of proximity to symptom onset.
Contributorship

CH and JR contributed to the study design, acquisition, analysis and interpretation of the data as well as drafting and revising the manuscript. All other authors (MSF, AH, HZ, KMM, RSC, MB, MN, DMC, DLT, CVG, IOCW, RS, JCVS, FM, RSV, BB, RIJ, MM, MCT, CG, DG, JBR, EF, MS, RV, AdM, FT, IS, SD, CB, AG, JL, AD, GF, SS, MO) contributed to the acquisition of data and study co-ordination as well as helping to critically review and revise the manuscript.

Acknowledgments

We particularly extend our appreciation to the members of these kindreds who have been active participants in the GENFI study.

Funding Statement

The GENFI study has been supported by the Medical Research Council UK (MR/M023664/1), the Italian Ministry of Health and the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, as well as other individual funding to investigators. This work was supported by the NIHR Queen Square Dementia Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility, Alzheimer’s Research UK, the Brain Research Trust and the Wolfson Foundation as well as an Alzheimer’s Society grant (AS-PG-16-007). The biomarker measurements were funded in part by the UK Dementia Research Institute at UCL and by a Wellcome Trust Multi-User Equipment Grant. KM has received funding from an Alzheimer’s Society PhD studentship. IOCW is supported by a MRC Clinical Research Training Fellowship (MR/M018288/1). RS is supported by an Alzheimer’s Research UK Clinical Research Training Fellowship (ARUK-CRF2017B-2). JCVS was supported by the Dioraphte Foundation grant 09-02-03-00, the Association for Frontotemporal Dementias Research Grant 2009, The Netherlands Organization for Scientific Research (NWO) grant HCMI 056-13-018, ZonMw Memorabel (Deltaplan Dementie, project number 733 051 042), Alzheimer Nederland and the Bluefield project. CG received funding from JPND-Prefrontals VR Dnr 529-2014-7504, VR: 2015-02926, and 2018-02754, the Swedish FTD Initiative-Schörling Foundation, Alzheimer Foundation, Brain Foundation and Stockholm County Council ALF. DG received support from the EU Joint Programme – Neurodegenerative Disease Research (JPND) and the Italian Ministry of Health (PreFrontALS) grant 733051042. RSV has received funding from Fundació Marató de TV3, Spain (grant no. 20143810). FM received funding from the Tau Consortium and the Center for Networked Biomedical Research on Neurodegenerative Disease (CIBERNED). JBR has received funding from the Wellcome Trust (103838) and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. MO has received funding from BMBF (FTLDc). MM has received funding from a Canadian Institutes of Health Research operating grant and the Weston Brain Institute and Ontario Brain Institute. RV has received funding from the Mady Browaeys Fund for Research into Frontotemporal Dementia. EF has received funding from a CIHR grant #327387. HZ is a Wallenberg Academy Fellow. JDR is a MRC Clinician Scientist (MR/M008525/1) and has received funding from the NIHR Rare Diseases Translational Research Collaboration (BRC149/NS/MH), the Bluefield Project and the Association for Frontotemporal Degeneration.
Competing of Interests

The authors declare no conflict of interest.
REFERENCES


20. Rascovksy, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of


Figure 1. a) Plasma GFAP and b) plasma NfL concentrations (pg/mL) in control, presymptomatic and symptomatic FTD mutation carriers for each gene: C9orf72, GRN and MAPT. Median designated by blue line; interquartile ranges indicated by orange error bars. * = significant differences – only differences from controls and within the same genetic group are shown on the graph. Note that 29 data points fall outside the upper or lower limit using the interquartile range method, with factor $k = 1.5$ (i.e. outside the upper limit Q3 + 1.5 x IQR or lower limit Q1 - 1.5 x IQR): excluding these outliers does not change the significance of the results.

Figure 2. Correlation between plasma GFAP concentrations (pg/mL) and age: a) presymptomatic, and b) symptomatic mutation carriers.